Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kjersti Flatmark

Showing results (41-50 of 133) with videos related to

Pageof 14
Sort By:
Acta Oncologica (Stockholm, Sweden)|August 9, 2022
Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine studyAnne Hansen Ree, Gunhild M Mælandsmo, Kjersti Flatmark, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|May 26, 2016
Expression and clinical significance of Wee1 in colorectal cancerEivind Valen Egeland, Kjersti Flatmark, Jahn M Nesland, et al.
Oncotarget|May 5, 2016
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancerSebastian Meltzer, Erta Kalanxhi, Helga Helseth Hektoen, et al.
Angiogenesis|August 12, 2011
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic disseminationMarie Grøn Saelen, Kjersti Flatmark, Sigurd Folkvord, et al.
Lung Cancer (Amsterdam, Netherlands)|February 12, 2008
Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patientsPaal Fr Brunsvig, Kjersti Flatmark, Steinar Aamdal, et al.
Critical Reviews in Oncology/Hematology|January 28, 2015
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapiesAnne Hansen Ree, Kjersti Flatmark, Marie Grøn Saelen, et al.
Radiation Oncology (London, England)|September 29, 2012
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinomaMarie Grøn Saelen, Anne Hansen Ree, Alexandr Kristian, et al.
Pleura and Peritoneum|March 23, 2026
High prevalence of <i>KRAS</i> and <i>GNAS</i> mutations in pseudomyxoma peritonei underscores opportunities for targeted therapeutic strategiesAnnette Torgunrud, Christin Lund-Andersen, Ben Davidson, et al.
Annals of Surgical Oncology|June 4, 2020
Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical MethodThale Dawn J H Patrick-Brown, Norman John Carr, David M Swanson, et al.
Scandinavian Journal of Surgery : SJS : Official Organ for the Finnish Surgical Society and the Scandinavian Surgical Society|October 3, 2023
Short-term results after robot-assisted surgery for primary rectal cancers requiring beyond total mesorectal excision in multiple compartmentsEbbe B Thorgersen, Arne M Solbakken, Tuva K Strøm, et al.
Pageof 14

Showing results (41-50 of 133) with videos related to

Sort By:
Pageof 14
Acta Oncologica (Stockholm, Sweden)|August 9, 2022
Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine studyAnne Hansen Ree, Gunhild M Mælandsmo, Kjersti Flatmark, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|May 26, 2016
Expression and clinical significance of Wee1 in colorectal cancerEivind Valen Egeland, Kjersti Flatmark, Jahn M Nesland, et al.
Oncotarget|May 5, 2016
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancerSebastian Meltzer, Erta Kalanxhi, Helga Helseth Hektoen, et al.
Angiogenesis|August 12, 2011
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic disseminationMarie Grøn Saelen, Kjersti Flatmark, Sigurd Folkvord, et al.
Lung Cancer (Amsterdam, Netherlands)|February 12, 2008
Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patientsPaal Fr Brunsvig, Kjersti Flatmark, Steinar Aamdal, et al.
Critical Reviews in Oncology/Hematology|January 28, 2015
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapiesAnne Hansen Ree, Kjersti Flatmark, Marie Grøn Saelen, et al.
Radiation Oncology (London, England)|September 29, 2012
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinomaMarie Grøn Saelen, Anne Hansen Ree, Alexandr Kristian, et al.
Pleura and Peritoneum|March 23, 2026
High prevalence of <i>KRAS</i> and <i>GNAS</i> mutations in pseudomyxoma peritonei underscores opportunities for targeted therapeutic strategiesAnnette Torgunrud, Christin Lund-Andersen, Ben Davidson, et al.
Annals of Surgical Oncology|June 4, 2020
Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical MethodThale Dawn J H Patrick-Brown, Norman John Carr, David M Swanson, et al.
Scandinavian Journal of Surgery : SJS : Official Organ for the Finnish Surgical Society and the Scandinavian Surgical Society|October 3, 2023
Short-term results after robot-assisted surgery for primary rectal cancers requiring beyond total mesorectal excision in multiple compartmentsEbbe B Thorgersen, Arne M Solbakken, Tuva K Strøm, et al.
Pageof 14